Physician profile
Alejandro Lee Suarez
NPI 1386936110
$210,274.04
in general payments reported to CMS, 2019-2025
43 companies · $11K in 2025
The $11K reported for 2025 was more than what 93% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50K · 2020: $45K · 2021: $57K · 2022: $33K · 2023: $5,789 · 2024: $8,298 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Food and Beverage: $6,120 · Education: $23.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,200.00 |
| Food and Beverage | $6,119.62 |
| Education | $23.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $202,648.78 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $952.73 | 2020-2025 | Stelara, Tremfya, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $946.07 | 2019-2024 | Trulance, Xifaxan, Relistor |
| Celgene Corporation | $565.92 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $471.61 | 2019-2025 | Entyvio, Eohilia |
| Boston Scientific Corporation | $418.20 | 2019-2025 | Exalt Model D, Radial Jaw 4 |
| Qol Medical, LLC | $415.44 | 2019-2025 | Sucraid |
| Cook Medical LLC | $391.52 | 2019-2021 | |
| Gilead Sciences, INC. | $373.27 | 2020-2025 | |
| Pfizer INC. | $336.48 | 2019-2025 | |
| Genzyme Corporation | $334.79 | 2022-2025 | |
| Ardelyx, INC. | $300.88 | 2022-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $243.91 | 2022-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $176.93 | 2020-2025 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $169.03 | 2024-2025 | Voquezna |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $151.01 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $134.80 | 2021-2023 | |
| Ironwood Pharmaceuticals, INC | $130.11 | 2020-2023 | Linzess |
| Redhill Biopharma INC. | $120.22 | 2020-2022 | |
| Braintree Laboratories, INC. | $109.96 | 2019-2024 | Sutab, Suflave |
| Lilly USA, LLC | $92.21 | 2024-2025 | Omvoh |
| Amgen INC. | $77.03 | 2020-2023 | Avsola, Amjevita |
| Vivus LLC | $68.63 | 2021-2025 | Pancreaze |
| Novo Nordisk INC | $58.37 | 2025 | Wegovy |
| Madrigal Pharmaceuticals | $56.24 | 2024-2025 | Rezdiffra, Resmetirom |
| Aimmune Therapeutics, INC. | $48.49 | 2024-2025 | Zenpep |
| Axonics, INC. | $47.64 | 2022-2024 | Axonics |
| Endogastric Solutions, INC | $47.58 | 2019-2022 | |
| Daiichi Sankyo INC. | $47.05 | 2020-2023 | Injectafer |
| Shire North American Group INC | $44.58 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $36.70 | 2025 | Iqirvo |
| Ferring Pharmaceuticals INC. | $35.04 | 2020-2023 | Rebyota |
| Sandoz INC. | $28.98 | 2024-2025 | Hyrimoz |
| Organon LLC | $27.49 | 2024 | |
| Celltrion USA INC. | $23.63 | 2024 | Zymfentra |
| Abbott Laboratories | $23.23 | 2023 | Epic |
| Romark Laboratories, Lc | $21.25 | 2019 | |
| Lucid Diagnostics INC. | $19.78 | 2025 | |
| Evoke Pharma, INC. | $16.76 | 2024 | |
| Shionogi INC | $16.51 | 2019 | |
| Merck Sharp & Dohme LLC | $15.34 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $14.95 | 2022 | |
| Pharmacosmos Therapeutics INC. | $14.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Suarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.